This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-02 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Among shark species, the white shark is responsible for the largest number of recorded shark bites on humans, with 351 documented unprovoked bites since 1580 as of 2024. The majority of them have been non-fatal, while 59 resulted in death. White sharks do not appear to find humans suitable as prey, though cases of consumption have been reported. While a white shark was blamed for the Jersey Shore shark attacks of 1916, some experts suspect a bull shark was responsible. In 1984, Tricas and McCosker proposed the "mistaken identity" hypothesis, suggesting that white sharks attack humans because surfboards create a silhouette similar to seals. A 2021 study supported this theory, concluding that sharks are likely colorblind and unable to distinguish between a seal and a swimming human. Other researchers have disputed this, proposing instead that these are "exploratory bites." A 2016 study found that most bites on surfers are too superficial to kill a seal and compared them to "test bites" made on inanimate objects. Similarly, a 2023 paper criticized the "mistaken identity" hypothesis for overemphasizing vision while neglecting other senses. The authors conclude that "sharks don't make 'mistakes' but instead continually explore their environments and routinely investigate novel objects as potential prey by biting them". A 2025 drone study of white shark "hotspots" found no documented aggression towards humans during encounters. White sharks infrequently bite boats.
In the above case, the dehydrogenase has transferred a hydride while releasing a proton, H+, but dehydrogenases can also transfer two hydrogens, using FAD as an electron acceptor. This would be depicted as AH2 + B ↔ A + BH2. A double bond is normally formed in between the two atoms that the hydrogens were taken from, as in the case of succinate dehydrogenase. The two hydrogens have been transferred to the carrier or the other product, with their electrons.
In response to the February 1945 Yalta Conference directives, a Polish Provisional Government of National Unity was formed in June 1945 under Soviet auspices; it was soon recognized by the United States and many other countries. The Soviet domination was apparent from the beginning, as prominent leaders of the Polish Underground State were brought to trial in Moscow (the "Trial of the Sixteen" of June 1945). In the immediate post-war years, the emerging communist rule was challenged by opposition groups, including militarily by the so-called "cursed soldiers", of whom thousands perished in armed confrontations or were pursued by the Ministry of Public Security and executed. Such guerillas often pinned their hopes on expectations of an imminent outbreak of World War III and defeat of the Soviet Union. The Polish right-wing insurgency faded after the amnesty of February 1947. The Polish people's referendum of June 1946 was arranged by the communist Polish Workers' Party to legitimize its dominance in Polish politics and claim widespread support for the party's policies. Although the Yalta agreement called for free elections, the Polish legislative election of January 1947 was controlled by the communists. Some democratic and pro-Western elements, led by Stanisław Mikołajczyk, former prime minister-in-exile, participated in the Provisional Government and the 1947 elections, but were ultimately eliminated through electoral fraud, intimidation and violence.
Sources: en.wikipedia.org
=== Low-intensity conflict (8 April – 24 May) === On 8 April, the Taliban-run Afghan foreign ministry stated that talks with Pakistani officials in China had concluded and described the discussions as constructive. Chinese officials said that representatives of Pakistan and the Taliban had agreed to work toward an early easing of tensions and to avoid actions that could escalate the situation. Pakistani officials did not comment on the outcome of talks. On the same day, Amir Khan Muttaqi, the Taliban's foreign minister, said while meeting with diplomats from Central Asian states that the group would not permit Afghan territory to be used by any group to threaten neighboring states. Although he did not name any organisation, he said the presence of such elements anywhere was unacceptable and that the Taliban intended to deal with the matter. He also stated that the Taliban were committed to easing tensions with Pakistan through dialogue and said he hoped the talks would produce positive outcomes. However, on 9 April, Mohammad Naeem Wardak, the Taliban's deputy foreign minister, said that talks between Pakistani and Taliban officials in China had ended without agreement and attributed their failure to Pakistani officials. On 10 April, local elders in Kunar and Nuristan said that Taliban border forces had withdrawn from several border posts in Bari Kot in Nari district, Kunar, and in Kamdesh district, Nuristan, and had taken shelter in village mosques.
==== Dengue epidemic ==== In 2024, the number of deaths from dengue in the country surged (6,041), an increase of 400% compared with 2023 (1,179), surpassing the deaths from COVID-19 (5,960) in that year (2024). Dengue deaths in 2024 exceeded the total for the previous eight years (4,992). The explosion in dengue cases led opposition deputies from the PL to nickname Lula "presidengue" and share false and exaggerated data about the number of deaths resulting from this small-scale epidemic.
== Measuring and processing the interferogram == The interferogram has to be measured from zero path difference to a maximum length that depends on the resolution required. In practice the scan can be on either side of zero resulting in a double-sided interferogram. Mechanical design limitations may mean that for the highest resolution the scan runs to the maximum OPD on one side of zero only. The interferogram is converted to a spectrum by Fourier transformation. This requires it to be stored in digital form as a series of values at equal intervals of the path difference between the two beams. To measure the path difference a laser beam is sent through the interferometer, generating a sinusoidal signal where the separation between successive maxima is equal to the wavelength of the laser (typically a 633 nm HeNe laser is used). This can trigger an analog-to-digital converter to measure the IR signal each time the laser signal passes through zero. Alternatively, the laser and IR signals can be measured synchronously at smaller intervals with the IR signal at points corresponding to the laser signal zero crossing being determined by interpolation. This approach allows the use of analog-to-digital converters that are more accurate and precise than converters that can be triggered, resulting in lower noise.
Sources: en.wikipedia.org
Jeremy Isaacs (born 28 September 1932) author of four books; creator of The World at War, British documentary television series chronicling the events of the Second World War recipient of many British Academy Television Awards and International Emmy Awards; won the British Film Institute Fellowship in 1986, the International Emmy Directorate Award in 1987 and the BAFTA Fellowship in 1985, General Director of the Royal Opera House, Covent Garden from 1987 to 1996; was the founding chief executive of Channel 4 between 1981 and 1987. Jonathan Israel (b. 1946); historian specialising in Dutch history, the Age of Enlightenment, Spinoza's Philosophy and European Jews; Professor at Institute for Advanced Study, Princeton, New Jersey, previously Professor at University College London; has focused his attention on multi-volume history of the Age of Enlightenment, contrasting two camps; "radical Enlightenment" was founded on rationalist materialism articulated by Spinoza and in opposition was "moderate Enlightenment" which he sees as weakened by its belief in God. Naomi Jacob, (1 July 1884 – 27 August 1964), also known by the pen name Ellington Gray, was an English writer, actress, broadcaster and lesbian of Jewish origin. Her father rejected his Jewish ancestry but Naomi Jacob embraced it. Joseph Jacobs folklorist Howard Jacobson (born 1942) author; has described himself as "a Jewish Jane Austen" (in response to being described as "the English Philip Roth"), and also states, "I'm not by any means conventionally Jewish. I don't go to shul.
== Interpretation == If the positive or negative controls fail, than the entire testing procedure is invalid and must be repeated. Criteria for a positive MMA will vary by laboratory, though the originally established threshold set by Sandra Nance et al., is >20% phagocytic activity observed. Clinically, a positive MMA would indicate that the patient's serum used in the assay contains clinically significant antibodies that are capable of causing antibody-mediated phagocytosis.
The PAH world hypothesis is a speculative hypothesis that proposes that polycyclic aromatic hydrocarbons (PAHs), known to be abundant in the universe, including in comets, and assumed to be abundant in the primordial soup of the early Earth, played a major role in the origin of life by mediating the synthesis of RNA molecules, leading into the RNA world. However, as yet, the hypothesis is untested.
=== Pharmacodynamics === SR-17018 acts as a biased partial agonist of the μ-opioid receptor (MOR), with strong selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its affinities (Ki) for the human opioid receptors have been reported to be 11 nM for the MOR, 68 nM for the κ-opioid receptor (KOR), and >10,000 nM for the δ-opioid receptor (DOR). In terms of MOR activation, the drug had activational potencies and efficacies (EC50Tooltip half-maximal effective concentration and EmaxTooltip maximal efficacy) of 97–193 nM (72–75%) for GTPγS binding, 76 nM (105%) for cAMPTooltip cyclic adenosine monophosphate accumulation, and >10,000 nM (10%) for β-arrestin2 recruitment. Both GTPγS binding and cAMP accumulation are measures of G protein signaling. The drug showed a calculated bias factor for GTPγS binding over β-arrestin2 recruitment of 80 to 100 relative to DAMGO. SR-17018 also showed strong bias for G protein activation over β-arrestin2 recruitment using mouse proteins, albeit with reduced efficacy for GTPγS binding (Emax = 37%). β-Arrestin2 activation may contribute to opioid tolerance, though it is not the only mechanism of tolerance to these drugs. SR-17018 shows a strikingly different MOR phosphorylation profile from other MOR biased, partial, and full agonists. Additional studies have characterized the interactions of SR-17018 with the MOR, including activational potencies and efficacies at downstream signaling pathways, as well.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.